CytRx Faces Nasdaq Delisting Hearing

Apr 28, 2004

NEW YORK, April 28 (GenomeWeb News) - CytRx faces a May 13 hearing before the Nasdaq Qualifications Panel over a possible delisting of the company's common stock from the Nasdaq Small Cap market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

Jennifer Doudna, Feng Zhang Awarded NHGRI Grants for CRISPR-Based Research
BRCA1/2 LOH Testing May Offer Treatment Response Clues in Some Cancer Cases
Mass General, CRISPR Therapeutics to Develop Cancer Therapies
Jackson Laboratory Team Wins $2.1M NIH Grant to Develop RNA Analysis Tech
Cholesterol-Regulating Gene Variant Found to Affect Bacterial Infection Susceptibility
Genomic Analysis of Wilms Tumors Leads to Kidney Development-Related Pathways

The Scan

Out of the Books

NPR reports that Turkish high school students will no longer study evolution.

Mountainside Sequencing

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

Better Treatments Sought

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

This Week in PNAS

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.

Main menu